PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT / ATTORNEY-CLIENT COMMUNICATION This memorandum is protected from disclosure by the attorney work-product doctrine and the attorney-client privilege. It is prepared in anticipation of litigation and reflects the mental impressions, conclusions, opinions, and legal theories of counsel. Any disclosure of this document to a third party may constitute a waiver of these protections and is strictly prohibited without prior authorization from the undersigned or the Responsible Partner.
CALDERWOOD & HARKNESS LLP 600 Lexington Avenue, 30th Floor New York, NY 10022
MEMORANDUM
TO: Linda Osei, Responsible Partner, Litigation (General) Priya Anand, Billing Partner, Litigation (General)
FROM: Patrick Gallagher, Lead Associate, Litigation (General)
DATE: September 15, 2025
RE: Litigation Strategy — Meridian Consumer Brands LLC v. Apex Naturals Inc.
MATTER NO.: 1011-00004
CLIENT: Meridian Consumer Brands LLC
SUBJECT MATTER: False Advertising / Unfair Competition Action Against Apex Naturals Inc.
Right-click to update Table of Contents
I. EXECUTIVE SUMMARY
Calderwood & Harkness LLP ("C&H" or the "Firm") was retained by Meridian Consumer Brands LLC ("Meridian" or "MCB") on September 8, 2025 to prosecute a false-advertising and unfair-competition action against Apex Naturals Inc. ("Apex" or "ANI"). This memorandum sets forth the Firm's recommended litigation strategy, including forum selection, causes of action, preliminary injunction strategy, damages theories, discovery plan, anticipated defenses, and timeline for key milestones.
The dispute arises from Apex's launch of a comparative advertising campaign branded "The PuraClear Truth" on June 2, 2025. That campaign makes demonstrably false superiority claims about Apex's PuraClear acne-treatment line relative to Meridian's flagship DermaTrūe product family. The campaign has been disseminated nationally through television, digital and social media platforms, in-store point-of-sale materials, print advertisements, and a dedicated campaign webpage. Apex's total estimated campaign spend from June through August 2025 is approximately $23.0 million, reflecting a concerted and heavily funded effort to reposition PuraClear at DermaTrūe's expense.
The campaign features three categories of false claims that form the core of the proposed action: (1) fabricated clinical-study data purporting to show that PuraClear reduces visible acne blemishes "47% faster" than DermaTrūe, supported by a citation to a non-existent peer-reviewed study; (2) misleading price-per-unit comparisons that deceptively juxtapose a single 1.0 oz. PuraClear product against a 5.2 oz. DermaTrūe multi-piece kit, creating a false impression of price superiority that is in fact reversed on a per-ounce basis; and (3) false "clean" ingredients superiority claims asserting that PuraClear is free of parabens, sulfates, and synthetic fragrances "unlike DermaTrūe," when Meridian's reformulated DermaTrūe Pure line is in fact also free of all three categories of ingredients.
Meridian has suffered significant, quantifiable, and ongoing harm as a direct result of the campaign. DermaTrūe Q3 2025 revenue declined 20.1% ($7.4 million) compared to Q3 2024. Consumer-perception survey data show a sharp and measurable shift in public attitudes toward DermaTrūe, with the proportion of consumers viewing the brand as "overpriced" tripling from 11% to 34% and the proportion viewing DermaTrūe as "less effective than PuraClear" rising from 8% to 27%. Additionally, Kingsley Drug Stores LLC, a national retail chain with over 2,400 stores, notified Meridian on August 5, 2025 that it is reducing DermaTrūe shelf space by 30% effective October 1, 2025, citing declining consumer demand — an action that is estimated to cost Meridian an additional $4.1 million in annual revenue.
Based on the strength of the factual record and the urgency of the ongoing harm, this memorandum recommends filing a Verified Complaint and accompanying Motion for Preliminary Injunction in the United States District Court for the Southern District of New York on or before September 26, 2025. The filing will assert five causes of action: (1) false advertising under the Lanham Act § 43(a), 15 U.S.C. § 1125(a); (2) deceptive acts and practices under New York General Business Law § 349; (3) false advertising under NY GBL § 350; (4) common-law unfair competition; and (5) tortious interference with business relations. The relief sought will include injunctive relief compelling the immediate cessation of the campaign; compensatory damages estimated at $18.5 million in annualized lost profits; disgorgement of approximately $11.2 million in Apex's ill-gotten profits; potential treble damages of up to $55.5 million based on the willfulness of Apex's conduct; corrective advertising; and attorneys' fees.
The engagement team for this matter consists of Linda Osei (Responsible Partner), Priya Anand (Billing Partner), Patrick Gallagher (Lead Associate), and Simone Laroche (Working Associate), with paralegal support as needed. Expert support has been secured or is in the process of being retained, including Dr. Eleanor Fisk (consumer-perception survey expert), Dr. Raymond Choe (damages expert), and Dr. Miriam Salazar (dermatology and scientific expert).
II. BACKGROUND AND KEY FACTS
A. The Parties
Meridian Consumer Brands LLC (Plaintiff)
Meridian Consumer Brands LLC is a Delaware limited liability company with its principal place of business at 410 West 34th Street, 18th Floor, New York, New York 10001. Meridian is registered to do business in the State of New York and maintains its registered agent at Capitol Filing Services Inc., 28 Liberty Street, Suite 4400, New York, New York 10005.
Meridian is a leading developer, manufacturer, and marketer of premium skincare, personal-care, and over-the-counter dermatological products. Meridian's portfolio of consumer brands includes DermaTrūe (a comprehensive acne and blemish treatment line), Velara (an anti-aging skincare line), and SkinSense (a sensitive-skin product line). Each brand occupies a distinct market segment and enjoys significant consumer recognition and loyalty, cultivated through years of investment in product development, marketing, and distribution relationships.
For the fiscal year ended December 31, 2024, Meridian reported total revenue of $487.6 million, as audited by Ashford & Kline LLP. The DermaTrūe product line alone accounted for $138.2 million of that total, representing 28.3% of Meridian's consolidated revenue and establishing DermaTrūe as the single most important brand in Meridian's portfolio. The DermaTrūe line operates at a gross margin of 62.5%, reflecting the premium positioning of the brand and the significant value added through Meridian's proprietary formulations and research-backed product development.
Meridian is owned by Brindoval Capital Partners Fund IV LP, a private equity fund that acquired the company in 2019. Key personnel at Meridian relevant to this matter include Nathan Hartwell (Chief Executive Officer), Julia Whitmore (Chief Marketing Officer), Derek Cho (General Counsel), and Dr. Annika Patel (Vice President, Regulatory & Scientific Affairs). Mr. Cho has served as the primary point of contact for engagement of this Firm and will continue to serve as the day-to-day client liaison throughout the litigation.
Apex Naturals Inc. (Defendant)
Apex Naturals Inc. is a Delaware corporation with its principal place of business at 75 Commerce Boulevard, Suite 300, Parsippany, New Jersey 07054. Apex maintains a registered agent in Delaware through Pinnacle Registered Agents LLC, 1209 Orange Street, Wilmington, Delaware 19801.
Apex operates in the mass-market and "clean-beauty" skincare and acne-treatment product segments. Its principal brands include PuraClear (an acne treatment line), GreenVeil (a moisturizer line), and ClearPath (a body wash line). Apex has positioned itself as a "natural" and "clean" alternative to established skincare brands, and its PuraClear product line directly competes with Meridian's DermaTrūe family in the OTC acne-treatment category.
Based on publicly available information and industry data, Apex's total estimated revenue for fiscal year 2024 was approximately $312.4 million. The PuraClear line alone accounted for an estimated $89.7 million, or approximately 28.7% of Apex's total revenue, underscoring the strategic importance of the PuraClear brand to Apex's business. Key personnel at Apex relevant to this matter include Marcus Devlin (Chief Executive Officer and Founder), Rachel Emory (Chief Marketing Officer), Dr. Simon Guerrero (Vice President, Product Development), and Tanya Fischetti (General Counsel).
Apex is represented in this matter by the law firm of Caldwell, Briggs & Nolan LLP ("CBN"), with offices at 200 Park Avenue, 42nd Floor, New York, New York 10166. The lead partner assigned to the matter is Harrison Briggs, with associate Leah Tannenbaum also appearing on behalf of Apex. C&H has had prior dealings with CBN in unrelated matters and is familiar with the firm's litigation practices and approach.
B. The Advertising Campaign
The advertising campaign at the center of this dispute is branded "The PuraClear Truth." Internal documents obtained through Meridian's pre-litigation investigation indicate that the campaign was developed under the internal code name "Project Clarity" at Apex. The campaign was created by Brightline Creative Partners LLC, a Brooklyn-based advertising and creative agency led by Owen Prescott (Chief Creative Officer), with offices at 55 Washington Street, Suite 900, Brooklyn, New York 11201. Brightline served as Apex's agency of record for the PuraClear brand during the relevant period.
"The PuraClear Truth" campaign launched on June 2, 2025, and has been disseminated across an extensive array of media channels, reflecting Apex's intent to maximize the reach and impact of its comparative messaging. Specifically, the campaign has been deployed through the following channels:
• National Television: 30-second and 60-second spot advertisements airing on major broadcast and cable networks during prime time and daytime programming.
• Digital Video: Pre-roll and mid-roll advertisements on Crowne Albany Partners LLC, sponsored content and advertisements on Dunmore & Co., and paid video advertisements through Northpoint Services Inc. Reels.
• In-Store Point-of-Sale Displays: Physical display materials positioned adjacent to PuraClear products in major drugstore chains, including signage, shelf talkers, and end-cap promotional displays.
• Print Advertisements: Full-page and half-page advertisements in national consumer magazines in the health, beauty, and lifestyle categories.
• Dedicated Campaign Webpage: A purpose-built webpage located at www.apexnaturals.com/puraclear-truth, which aggregates the campaign's claims with supporting graphics and an embedded video version of the television spots.
Based on available information, Apex's total estimated campaign expenditure for the period of June through August 2025 was approximately $23.0 million, allocated as approximately $14.3 million for television advertising and approximately $8.7 million for digital and social media advertising. These figures do not include the cost of in-store materials or print advertisements, which are expected to add meaningfully to the total campaign investment. The scale of the campaign spend reflects a deliberate and sustained effort by Apex to saturate the market with its comparative claims.
C. The Three Categories of False Claims
The campaign is built around three core comparative claims, each of which is demonstrably false. These claims form the factual foundation for each of the five causes of action recommended in this memorandum.
1. Clinical Superiority Claim
The first and most prominent false claim is a comparative efficacy claim asserting that PuraClear is clinically superior to DermaTrūe. Specifically, the campaign states:
"In a controlled clinical study, PuraClear reduced visible acne blemishes 47% faster than the leading DermaTrūe treatment."
This claim is presented in both the television and digital video advertisements, typically accompanied by a lower-third graphic citation to "Guerrero et al., 2024, Independent Dermatological Review" as the purported source for the underlying clinical study. The campaign webpage features a similar claim with an expanded discussion of the purported study results.
Our investigation, conducted in coordination with Dr. Annika Patel (Meridian's VP, Regulatory & Scientific Affairs) and Dr. Miriam Salazar (our retained dermatology expert), has determined that no such study has been published in any peer-reviewed journal or recognized dermatological publication. The title "Independent Dermatological Review" does not correspond to any known scientific or medical journal indexed in PubMed, the Cochrane Library, or any other major biomedical database. Extensive searches conducted by Dr. Salazar's research team have confirmed that no publication bearing the citation "Guerrero et al., 2024" exists in any recognized repository of dermatological or clinical literature.
What Apex appears to rely upon is an internal, non-blinded pilot study involving only 22 participants, conducted without a control group and without adherence to established clinical-trial protocols. This pilot study is fundamentally incapable of supporting a comparative efficacy claim of the nature asserted in the campaign. As Dr. Salazar will testify, a reliable comparative efficacy study of this nature would require, at a minimum, a double-blinded design, an adequate control group (or head-to-head comparative arm), a statistically significant sample size (typically at least 100 participants per arm), a clearly defined primary endpoint, and compliance with Good Clinical Practice guidelines. Apex's 22-person, non-blinded pilot meets none of these criteria.
The citation to "Guerrero et al., 2024" — bearing the name of Apex's own Vice President of Product Development — as if it were an independent, peer-reviewed publication is particularly egregious and suggests a deliberate effort to lend a veneer of scientific credibility to an unsupported claim.
2. Misleading Price Comparison
The second false claim concerns a price comparison designed to create the impression that PuraClear offers comparable or superior acne treatment at a fraction of DermaTrūe's price. The campaign states:
"PuraClear delivers premium results at half the price — just $12.99 vs. $28.99 for a comparable DermaTrūe kit."
This claim is featured prominently in the television advertisements, in the digital and social media campaign, and in the in-store point-of-sale displays. It presents a facially simple price comparison — $12.99 versus $28.99 — that conveys the unmistakable message that PuraClear is the more affordable option.
However, the comparison is deeply misleading because it juxtaposes two fundamentally non-comparable products. The PuraClear product cited at the $12.99 price point is PuraClear Spot Treatment, a single 1.0 oz. tube. The per-ounce price of this product is therefore $12.99 per ounce. The DermaTrūe product cited at the $28.99 price point is the DermaTrūe Complete Acne System, a multi-step regimen kit containing three separate products: a 2.0 oz. cleanser, a 1.5 oz. treatment gel, and a 1.7 oz. moisturizer, for a total of 5.2 oz. of product. The per-ounce price of the DermaTrūe Complete Acne System is therefore $28.99 ÷ 5.2 oz. = approximately $5.57 per ounce.
When compared on the only meaningful basis — price per ounce — PuraClear's per-ounce cost ($12.99/oz.) is more than double that of DermaTrūe ($5.57/oz.). The campaign's price comparison thus conveys precisely the opposite of the truth. Far from delivering "premium results at half the price," the PuraClear Spot Treatment is, on a per-unit basis, the substantially more expensive product. The campaign's failure to disclose the dramatic volume disparity between the two products renders the comparison not merely misleading but affirmatively deceptive.
3. False "Clean" Ingredients Claim
The third false claim asserts that PuraClear is superior to DermaTrūe because it is free of certain ingredients that DermaTrūe purportedly contains. The campaign states:
"Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances."
This claim is featured across the television, digital, and in-store components of the campaign. It is designed to capitalize on growing consumer interest in "clean-beauty" products by positioning DermaTrūe as an outdated, ingredient-compromised brand relative to PuraClear.
The claim is literally false. In 2024, Meridian completed a comprehensive reformulation of its DermaTrūe product line, introducing a sub-brand designated "DermaTrūe Pure." The DermaTrūe Pure formulations are, in fact, entirely free of parabens, sulfates, and synthetic fragrances — the very ingredients that Apex claims DermaTrūe contains. The DermaTrūe Pure reformulation was widely publicized, featured in Meridian's 2024 marketing materials, and documented in updated ingredient lists filed with the FDA.
The falsity of Apex's claim has been independently confirmed by Beacon Scientific Laboratories LLC, an accredited independent testing laboratory located at 44 Industrial Parkway, Edison, New Jersey 08817. Lab Report No. BSL-2025-0412, dated March 15, 2025, provides a comprehensive ingredient analysis of the DermaTrūe Pure product line and confirms the absence of parabens, sulfates, and synthetic fragrances in all tested formulations. This report will be introduced as evidence in support of the Verified Complaint and the preliminary injunction motion.
D. Pre-Litigation Activity
The following chronology summarizes the pre-litigation activity undertaken by Meridian and its advisors prior to the Firm's retention:
June 18, 2025: Derek Cho, Meridian's General Counsel, sent a detailed cease-and-desist letter to Tanya Fischetti, Apex's General Counsel, demanding the immediate withdrawal of all "The PuraClear Truth" campaign materials and a public retraction of the three categories of false claims. The letter identified each false claim with specificity, explained the basis for Meridian's contention that the claims were false, and warned that Meridian would pursue all available legal remedies if Apex failed to comply.
July 3, 2025: Apex responded through its outside counsel, Harrison Briggs of Caldwell, Briggs & Nolan LLP. The response denied all allegations of falsity, asserted that the campaign claims were truthful and fully substantiated, and declined to withdraw or modify the campaign in any respect. The response did not identify any specific substantiation for the claims beyond a general assertion that Apex's internal research supported its advertising representations.
July 22, 2025: Meridian filed a complaint with the National Advertising Division ("NAD") of BBB National Programs, Case Reference NAD-2025-01847, challenging the clinical superiority and price-comparison claims. Meridian elected to pursue the NAD process in parallel with its consideration of litigation options.
August 15, 2025: The NAD issued a preliminary recommendation that Apex discontinue or modify the clinical superiority and price-comparison claims pending further substantiation. The NAD found that Apex's internal pilot study was insufficient to support the "47% faster" comparative efficacy claim and that the price comparison was misleading in light of the volume disparity between the compared products. Apex publicly stated that it would appeal the NAD's recommendation and declined to modify or withdraw the campaign.
September 2, 2025: Meridian engaged Beacon Scientific Laboratories LLC to conduct independent product-comparison testing of DermaTrūe Pure and PuraClear products, supplementing the laboratory's earlier March 2025 ingredient analysis.
September 8, 2025: Meridian formally retained Calderwood & Harkness LLP to prosecute the instant action.
E. Impact on Meridian
The impact of Apex's "The PuraClear Truth" campaign on Meridian's business has been substantial, measurable, and ongoing. The harm falls into three principal categories: direct revenue loss, brand-perception damage, and disruption of key distribution relationships.
Revenue Decline. DermaTrūe Q3 2025 revenue was $29.4 million, compared to $36.8 million in Q3 2024 — a decline of $7.4 million, representing a 20.1% year-over-year decrease. No other material changes in market conditions, product availability, or competitive activity account for this decline; the launch of Apex's campaign on June 2, 2025 is the only significant intervening event. At a gross margin of 62.5%, the estimated lost gross profit attributable to Q3 2025 alone is $4.625 million. Annualized, the lost-profit impact is estimated at $18.5 million, assuming the campaign continues unabated.
Brand-Perception Damage. The consumer-perception survey conducted by Fisk Analytics Group LLC (Dr. Eleanor Fisk, principal), fielded on August 22, 2025, provides robust quantitative evidence of the campaign's impact on consumer attitudes toward DermaTrūe. The survey employed a nationally representative sample of 1,500 adults, with a margin of error of ±2.5%. Key findings include:
• 34% of respondents who recalled PuraClear advertisements believed DermaTrūe was "overpriced," compared to an 11% baseline measured in a January 2025 survey — a threefold increase.
• 27% of respondents who recalled PuraClear advertisements believed DermaTrūe was "less effective than PuraClear," compared to an 8% baseline in January 2025 — a more than threefold increase.
These shifts in consumer perception are directly attributable to the campaign's false claims and represent the type of intangible but deeply damaging brand injury that monetary relief alone cannot fully remedy.
Loss of Retail Distribution. On August 5, 2025, Kingsley Drug Stores LLC — a national retail chain with more than 2,400 stores and one of Meridian's most significant distribution partners for the DermaTrūe line — notified Meridian that it was reducing DermaTrūe shelf space by 30% effective October 1, 2025. Kingsley cited declining consumer demand for DermaTrūe products as the basis for the decision. The estimated annual revenue impact of this reduction is $4.1 million. The Kingsley decision is both a direct consequence of Apex's false advertising and a harbinger of potential further distribution erosion if the campaign is permitted to continue.
The cumulative effect of these impacts threatens not only Meridian's near-term financial performance but also the long-term viability and market position of the DermaTrūe brand — a brand in which Meridian and its parent, Brindoval Capital Partners Fund IV LP, have invested significant capital over many years.
III. FORUM SELECTION
A. Recommended Forum: U.S. District Court for the Southern District of New York
We recommend filing the Verified Complaint and Motion for Preliminary Injunction in the United States District Court for the Southern District of New York. This forum provides the strongest combination of favorable substantive law, procedural advantages, and practical convenience for the prosecution of this action.
Subject-Matter Jurisdiction. The court has federal question jurisdiction under 28 U.S.C. § 1331 based on the principal federal claim asserted under the Lanham Act § 43(a), 15 U.S.C. § 1125(a). The court may exercise supplemental jurisdiction under 28 U.S.C. § 1367 over the related state-law claims arising from New York General Business Law §§ 349 and 350, common-law unfair competition, and tortious interference with business relations, as all claims arise from a common nucleus of operative fact — Apex's false advertising campaign.
Alternatively, subject-matter jurisdiction is independently available under the diversity jurisdiction statute, 28 U.S.C. § 1332. Meridian is a Delaware limited liability company with its principal place of business in New York. For diversity purposes, the citizenship of an LLC is determined by the citizenship of all its members; we are in the process of confirming the citizenship of all members of Meridian through the Brindoval Capital Partners Fund IV LP ownership chain, and we do not anticipate any impediment to establishing complete diversity. Apex is a Delaware corporation with its principal place of business in Parsippany, New Jersey, making it a citizen of both Delaware and New Jersey for diversity purposes. The amount in controversy well exceeds the $75,000 statutory threshold, as Meridian's claimed damages are in the tens of millions of dollars.
B. Personal Jurisdiction Over Apex
The Southern District of New York has personal jurisdiction over Apex Naturals Inc. on both general and specific jurisdiction grounds.
Apex conducts substantial and continuous business in New York, including the marketing and sale of PuraClear and other Apex products through retail channels within the Southern District. The challenged advertisements were disseminated via national television broadcasts received within the district, digital platforms accessed by New York consumers, and in-store point-of-sale displays at retail locations within the district. The dedicated campaign webpage at www.apexnaturals.com/puraclear-truth is accessible to and targeted at consumers in New York.
Specific personal jurisdiction is clearly appropriate because the claims arise directly from Apex's advertising activities directed at New York consumers and the harm suffered by Meridian at its New York headquarters. General jurisdiction may also be available based on the breadth and continuity of Apex's New York business activities, though we do not anticipate needing to rely on general jurisdiction.
C. Venue
Venue is proper in the Southern District of New York under 28 U.S.C. § 1391(b), which provides that a civil action may be brought in a district where a substantial part of the events or omissions giving rise to the claim occurred. The advertising campaign was disseminated to consumers within the Southern District through multiple media channels. Meridian's principal place of business is located within the district, and the economic harm to Meridian — including lost revenue and brand-perception damage — has been suffered at that location. The decision by Kingsley Drug Stores to reduce DermaTrūe shelf space has implications for stores throughout the district.
D. Advantages of S.D.N.Y.
The Southern District of New York offers several material strategic advantages for the prosecution of this action:
Well-Developed Lanham Act Jurisprudence. The Second Circuit has one of the most robust and well-developed bodies of false-advertising jurisprudence under the Lanham Act in the country. Judges in the Southern District routinely handle complex false-advertising and trademark disputes and are thoroughly familiar with the applicable legal standards, including the distinction between literal falsity and implied falsity, the role of survey evidence, and the standards for preliminary injunctive relief.
Favorable Preliminary Injunction Standards. The Second Circuit's framework for evaluating preliminary injunctions in Lanham Act false-advertising cases is favorable to Meridian's position. Where a plaintiff demonstrates literal falsity, the Second Circuit recognizes a presumption of consumer deception, which obviates the need for survey evidence to establish likelihood of confusion — though we will present survey evidence to reinforce the case. The irreparable-harm framework in the Second Circuit is also well-suited to cases involving ongoing false advertising by a direct competitor.
Proximity and Convenience. The Southern District is optimally situated for the efficient prosecution of this matter. Calderwood & Harkness's offices are located at 600 Lexington Avenue. Meridian's principal place of business is at 410 West 34th Street. Key witnesses, including Julia Whitmore (CMO), Derek Cho (General Counsel), and Dr. Annika Patel (VP, Regulatory & Scientific Affairs), are based in New York. Dr. Miriam Salazar is affiliated with Graystone University Medical Center in New York.
Judicial Familiarity with Complex Commercial Litigation. The Southern District is widely recognized as one of the preeminent venues for complex commercial litigation in the United States. The judges of the court are experienced in managing multi-party, multi-issue commercial disputes involving extensive discovery and expert testimony.
E. Alternative Fora Considered and Rejected
We considered and rejected two alternative fora:
U.S. District Court for the District of New Jersey. While venue and personal jurisdiction would likely be available in the District of New Jersey (Apex's principal place of business is in Parsippany, NJ), the Third Circuit's precedent on irreparable-harm presumptions in Lanham Act cases is less favorable than the Second Circuit's. Filing in New Jersey would also be less convenient for Meridian's personnel and for C&H, and would require travel for most key witnesses.
New York State Supreme Court. State court is less desirable because the Lanham Act claim — the strongest claim in Meridian's portfolio — is a federal claim that cannot be adjudicated in state court. While the state-law claims could be pursued independently in state court, doing so would sacrifice the most potent cause of action and the full range of federal remedies, including disgorgement and treble damages. Additionally, state court discovery tools are generally less robust than those available under the Federal Rules of Civil Procedure, and state court injunction practice for advertising disputes is less well-developed.
IV. CAUSES OF ACTION
The Verified Complaint will assert five causes of action. The first — false advertising under the Lanham Act — is the principal federal claim and provides the broadest array of remedies. The four supplemental state-law claims provide additional theories of liability and damages that strengthen the overall case.
A. Count I: False Advertising Under the Lanham Act § 43(a), 15 U.S.C. § 1125(a)
Section 43(a) of the Lanham Act creates a federal cause of action against any person who, in commercial advertising or promotion, makes false or misleading representations of fact that are likely to cause damage to a competitor. The elements of a Lanham Act false-advertising claim are well-established:
(1) The defendant made a false or misleading statement of fact in commercial advertising or promotion;
(2) The statement actually deceives or has a tendency to deceive a substantial segment of the intended audience;
(3) The deception is material — that is, it is likely to influence the purchasing decisions of the intended audience;
(4) The advertised goods are in interstate commerce; and
(5) The plaintiff has been or is likely to be injured as a result of the false advertising.
Each element is satisfied with respect to all three categories of false claims at issue.
Literal Falsity. Meridian's primary theory is that each of the three claims is literally false, which is the strongest form of falsity under the Lanham Act. A claim is literally false when the advertising statement, on its face, conveys a false message. Where literal falsity is established, the plaintiff is relieved of the burden of proving actual consumer deception through survey evidence, as deception is presumed.
The clinical superiority claim ("47% faster") is literally false because the cited study — "Guerrero et al., 2024, Independent Dermatological Review" — does not exist in any peer-reviewed journal or recognized publication. Apex's sole support is a non-blinded, 22-person internal pilot study conducted without a control group, which is scientifically incapable of supporting a comparative efficacy claim. Dr. Miriam Salazar will provide expert testimony on this point.
The price comparison ("$12.99 vs. $28.99") is literally false on a per-unit basis because it compares a 1.0 oz. product to a 5.2 oz. multi-product kit without disclosing the volume disparity. The true per-ounce price comparison ($12.99/oz. for PuraClear vs. $5.57/oz. for DermaTrūe) reverses the advertised price advantage entirely.
The "clean" ingredients claim ("Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances") is literally false because DermaTrūe Pure is in fact also free of parabens, sulfates, and synthetic fragrances, as confirmed by Beacon Scientific Laboratories LLC in Lab Report No. BSL-2025-0412.
Implicit Falsity (Alternative Theory). In the alternative, if the court does not find literal falsity on any claim, Meridian will argue that the claims are implicitly misleading — that is, that they convey a false impression even if the words themselves are not literally untrue. Under this theory, consumer confusion can be demonstrated through the Dr. Fisk survey evidence, which shows dramatic shifts in consumer perception directly attributable to the campaign.
Standing. Meridian's standing to bring this claim is clear. As a direct competitor of Apex in the OTC acne-treatment market, Meridian falls squarely within the zone of interests protected by the Lanham Act. The concrete economic injury suffered — $7.4 million in Q3 2025 revenue decline, brand-perception damage, and loss of retail distribution — amply satisfies the injury-in-fact requirement.
B. Count II: Deceptive Acts and Practices Under NY GBL § 349
Section 349 of the New York General Business Law prohibits deceptive acts or practices in the conduct of any business, trade, or commerce. The elements are:
(1) The challenged conduct is consumer-oriented;
(2) The conduct is misleading in a material way; and
(3) The plaintiff suffered injury as a result.
The "PuraClear Truth" campaign is plainly consumer-oriented, as it consists of national advertising directed at retail consumers through television, digital media, in-store displays, and print. No showing of individual reliance is required under § 349; the applicable test is an objective one — whether the act or practice is likely to mislead a reasonable consumer acting reasonably under the circumstances. Each of the three false claims easily satisfies this standard.
Section 349 provides for statutory damages of $50 per violation (up to $1,000 for knowing or willful violations) as well as recovery of actual damages, treble damages for willful or knowing violations (up to $10,000), and attorneys' fees. While the statutory damages under § 349 are modest in comparison to the Lanham Act remedies, the availability of attorneys' fees and the independent consumer-protection basis for the claim add value to the overall action.
C. Count III: False Advertising Under NY GBL § 350
Section 350 of the New York General Business Law specifically targets false advertising, prohibiting advertising that is misleading in a material respect. The elements of a § 350 claim substantially overlap with those of § 349, but the statute focuses specifically on advertising conduct rather than the broader category of deceptive acts and practices.
The evidentiary basis for the § 350 claim is identical to that for the § 349 claim. The separate assertion of both claims is standard practice in New York false-advertising cases and ensures that the court has the full range of statutory remedies at its disposal. Section 350 provides for compensatory damages, injunctive relief, and, in appropriate cases, attorneys' fees.
D. Count IV: Common-Law Unfair Competition
Under New York common law, unfair competition encompasses a broad range of conduct involving misrepresentation likely to cause confusion or deception regarding the quality, characteristics, or source of goods. The common-law unfair competition claim provides an equitable theory of relief that supplements the statutory claims and reaches conduct that may not fit neatly within the statutory frameworks.
Meridian will establish that Apex engaged in unfair competition through the systematic dissemination of false comparative claims designed to divert consumers from DermaTrūe to PuraClear. The element of bad faith is demonstrated by Apex's refusal to withdraw the campaign after receiving Meridian's June 18, 2025 cease-and-desist letter, its rejection of the NAD's August 15, 2025 preliminary recommendation to discontinue or modify the challenged claims, and its knowledge (or constructive knowledge) that the cited clinical study does not exist in any peer-reviewed publication. The deliberate citation of a non-existent study under the name of Apex's own employee as if it were an independent, peer-reviewed publication reflects a calculated intent to deceive.
E. Count V: Tortious Interference with Business Relations
Meridian's fifth cause of action is for tortious interference with business relations, arising from the direct impact of Apex's campaign on Meridian's relationship with Kingsley Drug Stores LLC. The elements of a tortious interference claim under New York law are:
(1) The existence of a business relationship between the plaintiff and a third party;
(2) The defendant's knowledge of that relationship;
(3) The defendant's intentional interference causing the relationship to be breached or terminated; and
(4) Damages.
Meridian maintained a longstanding and commercially significant business relationship with Kingsley Drug Stores LLC, a national retail chain with more than 2,400 stores. On August 5, 2025, Kingsley notified Meridian that it was reducing DermaTrūe shelf space by 30% effective October 1, 2025, expressly citing declining consumer demand attributable to the PuraClear campaign. The estimated annual revenue impact of this reduction is $4.1 million.
Apex, as a direct competitor selling through the same retail channels, had actual or constructive knowledge of the Meridian–Kingsley business relationship. Apex's intentional dissemination of false comparative advertising, designed to erode consumer demand for DermaTrūe, constitutes the type of improper interference recognized under New York law. The causal connection between the campaign and Kingsley's decision is direct and documented.
V. PRELIMINARY INJUNCTION STRATEGY
A. Legal Standard
A preliminary injunction is an extraordinary remedy available to preserve the status quo and prevent irreparable harm during the pendency of litigation. In the Second Circuit, the standard for obtaining a preliminary injunction requires the movant to demonstrate:
(1) A likelihood of success on the merits;
(2) A likelihood of irreparable harm in the absence of preliminary relief;
(3) That the balance of hardships tips in the movant's favor; and
(4) That the injunction is in the public interest.
In Lanham Act false-advertising cases, the Second Circuit applies a modified framework that is particularly favorable to plaintiffs who can demonstrate literal falsity. Where a plaintiff establishes that the challenged advertising is literally false, the court may presume consumer deception without requiring the plaintiff to introduce survey evidence, although survey evidence may still be submitted to strengthen the showing. The presumption of irreparable harm has historically been available in the Second Circuit in cases involving direct competitors, and while the strength of this presumption has been subject to some refinement in recent years, courts in the Southern District continue to recognize it as a meaningful factor in the analysis.
B. Likelihood of Success on the Merits
Meridian can make a strong showing of likelihood of success on the merits with respect to all three categories of false claims.
Clinical Superiority Claim. The "Guerrero et al., 2024, Independent Dermatological Review" citation is to a non-existent publication. No peer-reviewed journal or recognized scientific publication bearing this title has been identified through comprehensive database searches. Apex's internal basis for the claim — a non-blinded, 22-participant pilot study with no control group — is scientifically inadequate to support a comparative efficacy claim of any kind, let alone a specific quantitative claim that PuraClear works "47% faster" than a named competitor. Dr. Miriam Salazar's expert testimony will detail the methodological deficiencies of the pilot study and the scientific standards that a valid comparative efficacy study would need to meet. The literal falsity of this claim is patent.
Price Comparison. The comparison of a 1.0 oz. PuraClear product ($12.99) to a 5.2 oz. DermaTrūe multi-product kit ($28.99) without any disclosure of the volume disparity is facially misleading. The true per-ounce comparison — $12.99/oz. for PuraClear versus $5.57/oz. for DermaTrūe — entirely reverses the price advantage that the advertisement conveys. The court need not look beyond the face of the advertisement and the products themselves to conclude that this claim is literally false.
"Clean" Ingredients Claim. The assertion that DermaTrūe, "unlike" PuraClear, contains parabens, sulfates, and synthetic fragrances is literally false as applied to the DermaTrūe Pure product line. Independent laboratory testing by Beacon Scientific Laboratories, documented in Lab Report No. BSL-2025-0412, confirms that DermaTrūe Pure is free of all three categories of ingredients.
NAD Recommendation. While not legally binding, the NAD's August 15, 2025 preliminary recommendation that Apex discontinue or modify the clinical superiority and price-comparison claims is a significant indicator of the strength of Meridian's position. Courts in the Second Circuit routinely cite NAD findings as persuasive authority in Lanham Act false-advertising cases, and the NAD's independent assessment bolsters Meridian's likelihood-of-success showing.
C. Irreparable Harm
Meridian faces ongoing and escalating irreparable harm that cannot be adequately remedied by monetary damages alone.
Presumption of Irreparable Harm. In false-advertising cases involving direct competitors, the Second Circuit has recognized a presumption of irreparable harm. This presumption is appropriate here, where Apex and Meridian are head-to-head competitors in the OTC acne-treatment market and the false advertising is ongoing.
Independent Demonstration of Irreparable Harm. Even absent the presumption, Meridian can independently demonstrate irreparable harm on multiple grounds:
• Revenue Decline: The 20.1% ($7.4 million) decline in DermaTrūe Q3 2025 revenue is a concrete and ongoing financial injury that will deepen with each passing day that the campaign continues.
• Brand-Perception Damage: The Fisk Analytics survey data document a dramatic shift in consumer perception that goes well beyond mere lost sales. The tripling of the "overpriced" perception (from 11% to 34%) and the more than threefold increase in the "less effective" perception (from 8% to 27%) represent an erosion of brand equity that has been built over years of investment. Once consumer trust and brand perception are degraded, they cannot be restored simply through an award of money damages; the rebuilding process is lengthy, uncertain, and expensive.
• Loss of Retail Distribution: The Kingsley Drug Stores 30% shelf-space reduction, effective October 1, 2025, represents a concrete and imminent loss of distribution access that will compound the existing harm. Shelf-space allocations in retail are difficult to recapture once lost, as competitors fill the vacated space and retailers develop new stocking patterns. This harm is quintessentially irreparable.
• Ongoing Daily Harm: The campaign continues to air and be disseminated every day. Each additional day of exposure compounds the damage to Meridian's brand, its consumer relationships, and its distribution partnerships.
D. Balance of Equities
The balance of equities tips decisively in Meridian's favor. Meridian faces the ongoing erosion of market share, brand reputation, consumer trust, and distribution relationships — all of which are difficult or impossible to fully restore through monetary relief. The harm is concrete, documented, and accelerating.
By contrast, the only hardship Apex would suffer from the issuance of a preliminary injunction is the loss of an advertising campaign that is built on demonstrably false claims. A party has no legitimate interest in continuing to disseminate false advertising. Apex's substantial investment in the campaign — estimated at $23.0 million — does not tip the balance in its favor; equitable considerations do not protect investment in unlawful conduct. As courts in the Second Circuit have repeatedly held, a defendant cannot claim hardship from being required to cease making false claims.
E. Public Interest
The public interest strongly favors the issuance of a preliminary injunction. There is a well-established public interest in truthful advertising, particularly in the context of health-related OTC products such as acne treatments. Consumers are harmed by false clinical efficacy claims that may lead them to rely on a product based on fabricated study results, by deceptive price comparisons that lead to uninformed purchasing decisions, and by false ingredient claims that mislead consumers seeking "clean" products. An injunction requiring the cessation of false advertising directly serves the public interest in consumer protection and market integrity.
F. Filing Timeline
The target filing date for both the Verified Complaint and the Motion for Preliminary Injunction, together with all supporting declarations and exhibits, is September 26, 2025. This date has been selected to maximize the time available for preparation while ensuring that the motion is before the court well in advance of the October 1, 2025 effective date of the Kingsley shelf-space reduction.
The supporting papers to be filed with the Motion for Preliminary Injunction will include:
• Memorandum of Law in Support of Motion for Preliminary Injunction, setting forth the legal argument for each of the four preliminary injunction factors with respect to all three false claims.
• Declaration of Julia Whitmore (CMO, Meridian Consumer Brands LLC), attaching exemplars of the challenged campaign materials (television spots, screenshots of digital advertisements, photographs of in-store displays, and printouts of the campaign webpage), DermaTrūe sales data demonstrating the Q3 2025 revenue decline, and the August 5, 2025 notification from Kingsley Drug Stores regarding the shelf-space reduction.
• Declaration of Dr. Eleanor Fisk, presenting the methodology and results of the consumer-perception surveys (January 2025 baseline and August 2025 post-campaign), including the specific findings regarding the increase in "overpriced" and "less effective" perceptions.
• Proposed Order, setting forth the specific terms of the requested injunctive relief.
We anticipate that Apex, through CBN, will seek two to three weeks to respond to the motion. Accordingly, we estimate that the court will schedule a hearing on the preliminary injunction motion approximately four to six weeks after filing, likely in late October to early November 2025. We will request an expedited briefing schedule in light of the imminent and ongoing harm.
G. Scope of Injunctive Relief Sought
The proposed preliminary injunction will seek the following relief:
(a) Immediate cessation of all dissemination of "The PuraClear Truth" campaign materials across all media channels, including national television, digital video (Crowne Albany Partners LLC, Dunmore & Co., Northpoint Services Inc. Reels), in-store point-of-sale displays, print advertisements, and the dedicated campaign webpage;
(b) Removal of the campaign webpage located at www.apexnaturals.com/puraclear-truth and all associated content;
(c) A prohibition on Apex's making of the clinical superiority claim ("47% faster"), the price-comparison claim ("$12.99 vs. $28.99"), and the "clean" ingredients claim ("Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances") — or any claims substantially similar thereto — in any advertising or promotional materials, pending final adjudication of this action; and
(d) A corrective advertising component requiring Apex to publish corrective statements, in a form and through channels to be approved by the court, acknowledging the inaccuracy of the claims made in "The PuraClear Truth" campaign and informing consumers that the claims have been enjoined by court order.
The corrective advertising component is appropriate in light of the documented shift in consumer perception and the need to mitigate the ongoing effects of the false claims even after the campaign is halted.
VI. DAMAGES THEORIES
A. Compensatory Damages — Lost Profits
Meridian's primary damages theory is compensatory damages measured by lost profits attributable to Apex's false advertising campaign. The lost-profits analysis begins with the observed revenue decline and applies the established gross-margin methodology.
DermaTrūe Q3 2025 revenue was $29.4 million, a decline of $7.4 million (20.1%) from the $36.8 million reported in Q3 2024. The DermaTrūe gross margin is 62.5%. Accordingly, the estimated lost gross profit attributable to Q3 2025 is:
$7.4 million × 62.5% = $4.625 million (Q3 2025 lost gross profit)
Annualized, the lost-profit estimate — assuming the campaign continues at its current intensity — is:
$4.625 million × 4 = $18.5 million (annualized lost gross profit)
This estimate is conservative, as it does not account for the additional revenue losses that will result from the Kingsley Drug Stores shelf-space reduction effective October 1, 2025, which is estimated to reduce DermaTrūe annual revenue by an additional $4.1 million. Nor does it reflect any acceleration of the revenue decline if additional retail partners follow Kingsley's lead, which is a real and foreseeable risk.
The total compensatory damages figure is likely to increase as discovery yields more granular data regarding Meridian's actual lost sales, the geographic distribution of harm, and the full scope of distribution disruption.
B. Disgorgement of Apex's Profits
Under Lanham Act § 35(a), 15 U.S.C. § 1117(a), the court has discretion to award the defendant's profits to the plaintiff. Disgorgement serves both compensatory and deterrent purposes and is available as an alternative or supplement to the plaintiff's own lost profits.
Based on available information, Apex's estimated incremental PuraClear revenue attributable to the campaign during Q2 and Q3 2025 is approximately $19.8 million. Apex's estimated gross margin on PuraClear products is approximately 56.5%. The estimated disgorgement is therefore:
$19.8 million × 56.5% = $11.187 million ≈ $11.2 million
Under the Lanham Act, the plaintiff need only prove the defendant's gross sales; the burden then shifts to the defendant to prove any deductible costs or expenses that should be subtracted from the gross sales figure. This burden-shifting framework is favorable to Meridian and places the onus on Apex to establish the appropriate deductions. Dr. Raymond Choe will develop a formal disgorgement model that isolates the incremental revenue attributable to the false advertising from PuraClear's organic sales trajectory.
C. Treble Damages
Under Lanham Act § 35(a), the court has discretion to award up to three times actual damages in cases involving willful false advertising. The treble-damages provision is designed to deter egregious conduct and to ensure that a defendant does not profit from knowing violations.
Meridian's willfulness argument is strong. Apex continued the campaign after receiving Meridian's June 18, 2025 cease-and-desist letter, which identified each false claim with specificity. Apex declined to withdraw or modify the campaign through its counsel's July 3, 2025 response. After the NAD issued its August 15, 2025 preliminary recommendation to discontinue or modify the clinical superiority and price-comparison claims, Apex publicly stated it would appeal and declined to make any changes. This course of conduct demonstrates a knowing and deliberate disregard for the falsity of the claims and a calculated decision to continue the campaign for as long as possible, even in the face of escalating evidence of its untruthfulness.
The potential treble damages are:
$18.5 million × 3 = $55.5 million
While the award of treble damages is discretionary, the strength of the willfulness evidence makes this a realistic component of the damages recovery in this case.
D. Corrective Advertising Costs
In addition to lost profits and disgorgement, Meridian is entitled to recover the costs of corrective advertising necessary to undo the consumer confusion and brand-perception damage documented by the Fisk Analytics survey. The cost of a counter-campaign will need to be quantified based on the scope and duration of Apex's campaign and the degree of consumer confusion to be remedied. Dr. Choe will develop a corrective advertising cost estimate as part of his formal damages analysis.
Given that Apex spent approximately $23.0 million on the campaign from June through August 2025, the corrective advertising costs necessary to reach the same audience and counteract the false impressions are likely to be substantial. Courts have recognized corrective advertising costs as a proper component of damages in Lanham Act false-advertising cases.